D-二聚体与减量阿哌沙班用于无诱因静脉血栓栓塞症延长治疗:Apidulcis研究
这项多中心前瞻性队列研究纳入732例首次无诱因静脉血栓栓塞症、已抗凝≥12个月的患者,按系列D-二聚体检测结果决定是否停药或给予减量阿哌沙班(2.5 mg每日两次)18个月。因停药组主要结局发生率高达7.3%,研究在计划中期分析后终止;停药组主要结局发生率1.1%,校正HR为8.2。结论认为不应基于D-二聚体检测决定是否延长抗凝,减量阿哌沙班对复发有高效性和安全性。
要点
- 系列D-二聚体阴性者停药后主要结局发生率为7.3%(95%CI 4.5-11.2)。
- D-二聚体阳性者接受减量阿哌沙班2.5 mg每日两次,主要结局发生率为1.1%(95%CI 0.4-2.6)。
- 停药组较阿哌沙班组主要结局风险升高,校正HR为8.2(95%CI 3.2-25.3)。
核心结论
- 在首次无诱因静脉血栓栓塞症抗凝≥1年的患者中,不应基于D-二聚体检测决定是否进一步延长抗凝。
- 结果证实减量阿哌沙班对复发具有高效性和安全性。
研究设计与样本
- 多中心前瞻性队列研究。
- 纳入732例18至74岁、首次无诱因静脉血栓栓塞症后已抗凝≥12个月的门诊患者。
- 采用商业检测方法和预设cutoff进行D-二聚体检测,基线抗凝期间D-二聚体阴性者停药并在第15、30、60天重复检测。
- 系列阴性者286例(39.1%)不接受抗凝,首次阳性者446例(60.9%)接受阿哌沙班18个月。
- 所有患者计划随访18个月,研究在计划中期分析后因主要结局发生率高而终止。
主要发现
- 停药组主要结局发生率为7.3%(95%CI 4.5-11.2),包括症状性近端深静脉血栓或肺栓塞复发、静脉血栓栓塞症死亡和大出血。
- 接受阿哌沙班组主要结局发生率为1.1%(95%CI 0.4-2.6)。
- 停药组较阿哌沙班组主要结局风险升高,校正HR为8.2(95%CI 3.2-25.3)。
局限性
- 研究在计划中期分析后因主要结局发生率高而终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
D-dimer assay is used to stratify patients with unprovoked venous thromboembolism (VTE) for the risk of recurrence. However, this approach was never evaluated since direct oral anticoagulants are available. With this multicenter, prospective cohort study, we aimed to assess the value of an algorithm incorporating serial D-dimer testing and administration of reduced-dose apixaban (2.5 mg twice daily) only to patients with a positive test. A total of 732 outpatients aged 18 to 74 years, anticoagulated for ≥12 months after a first unprovoked VTE, were included. Patients underwent D-dimer testing with commercial assays and preestablished cutoffs. If the baseline D-dimer during anticoagulation was negative, anticoagulation was stopped and testing repeated after 15, 30, and 60 days. Patients with serially negative results (286 [39.1%]) were left without anticoagulation. At the first positive result, the remaining 446 patients (60.9%) were given apixaban for 18 months. All patients underwent follow-up planned for 18 months. The study was interrupted after a planned interim analysis for the high rate of primary outcomes (7.3%; 95% confidence interval [CI], 4.5-11.2), including symptomatic proximal deep vein thrombosis (DVT) or pulmonary embolism (PE) recurrence, death for VTE, and major bleeding occurring in patients off anticoagulation vs that in those receiving apixaban (1.1%; 95% CI, 0.4-2.6; adjusted hazard ratio [HR], 8.2; 95% CI, 3.2-25.3). In conclusion, in patients anticoagulated for ≥1 year after a first unprovoked VTE, the decision to further extend anticoagulation should not be based on D-dimer testing. The results confirmed the high efficacy and safety of reduced-dose apixaban against recurrences. This trial was registered at www.clinicaltrials.gov as #NCT03678506.
引用
- Palareti G, Poli D, Ageno W, et al. D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study. Blood Adv. 2022. PMID: 35914222. doi:10.1182/bloodadvances.2022007973
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。